Dyne Therapeutics prices public offering at $8.25 per share, raising $200 million.

From GlobeNewswire: 2025-06-30 21:45:00

Dyne Therapeutics, Inc. (Nasdaq: DYN) announces the pricing of a public offering, expecting to raise $200.0 million from the sale of 24,242,425 shares at $8.25 per share. The offering, set to close on July 2, 2025, includes an option for underwriters to purchase an additional 3,636,363 shares. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are managing the offering. Dyne is focused on developing treatments for neuromuscular diseases like myotonic dystrophy and Duchenne muscular dystrophy, with additional programs in the pipeline for other conditions. Forward-looking statements caution potential risks and uncertainties. Contact Mia Tobias for investor inquiries and Stacy Nartker for media inquiries.



Read more at GlobeNewswire: Dyne Therapeutics Announces Pricing of $200.0 Million